Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma.

Matthew MeiNi-Chun TsaiJoycelynne PalmerSaro ArmenianRobert ChenSteven RosenStephen FormanLeslie PopplewellLarry KwakPeter MartinKami MaddocksDavid BondAlex F Herrera

Published in: Clinical lymphoma, myeloma & leukemia (2024)

The combination of BV and ibrutinib was active in r/r HL; however, given significant toxicity, it cannot be recommended for future development.

Keyphrases

oxidative stress
hodgkin lymphoma
chronic lymphocytic leukemia
current status
lipopolysaccharide induced
diffuse large b cell lymphoma
oxide nanoparticles